Food and Drug Administration, HHS.
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 12 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
Approval is withdrawn as of June 11, 2021.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 240-402-6980, Martha.Nguyen@fda.hhs.gov.
End Further Info
Start Supplemental Information
The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.
|ANDA 060164||Nystatin Ointment||Lederle Laboratories, Division of American Cyanamid Co., P.O. Box 8299, Pearl River, NY 10965.|
|ANDA 060521||Humatin (paromomycin sulfate) Capsules, Equivalent to (EQ) 250 milligrams (mg)/base||King Pharmaceuticals, 501 5th St., Bristol, TN 37620.|
|ANDA 061034||Lincomycin Hydrochloride (HCl)||The Upjohn Co. (formerly Pharmacia and Upjohn Co.), 7000 Portage Rd., Kalamazoo, MI 49001.|
|ANDA 061652||Oxytetracycline||Parke Davis, 201 Tabor Rd., Morris Plains, NJ 07950.|
|ANDA 061701||Tetracycline||Wyeth Pharmaceuticals, 1211 Sherwood Ave., Richmond, VA 23220.|
|ANDA 062032||Erypar (erythromycin stearate) Tablets, EQ 250 mg/base and EQ 500 mg/base||Parke Davis.|
|ANDA 076490||Lithium Carbonate Extended-Release Tablets, 450 mg||Hikma Pharmaceuticals USA Inc., 1809 Wilson Rd., Columbus, OH 43228.|
|ANDA 083001||Triamcinolone Acetonide Foam||Lederle Laboratories.|
|ANDA 084803||Chlorpromazine HCl Tablets, 10 mg|| Do.|
|ANDA 087635||Butalbital; Aspirin; Phenacetin; Caffeine, Tablets|| Do.|
|ANDA 090102||Ranitidine HCl Syrup, EQ 15 mg base/milliliters||Torrent Pharma Inc., 150 Allen Rd., Suite 102, Basking Ridge, NJ 07920.|
|ANDA 206736||Rifampin for Injection, 600 mg/vial||Watson Pharmaceuticals, Inc. (an indirect, wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.), 400 Interpace Pkwy., Building A, Parsippany, NJ 07054.|
Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of June 11, 2021. Approval of each entire application is withdrawn, including any strengths and dosage forms inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on June 11, 2021 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.
Start Printed Page 26059
End Supplemental Information
Dated: May 5, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2021-09980 Filed 5-11-21; 8:45 am]
BILLING CODE 4164-01-P